Thrombo-embolic events in cancer patients with impaired renal function
Ismaı̈l Elalamy, Joëlle Nortier(Université Libre de Bruxelles), Kristin Jochmans(Palmetto Hematology Oncology), Jeroen Mebis(Jessa Hospital), Marc Peeters(University of Antwerp), Lionel Duck, Lionel Bosquée(Centre Hospitalier Universitaire de Liège), Stéphane Holbrechts(CHU Ambroise Paré), Wim Lybaert(Vlaamse Vereniging voor Obstetrie en Gynaecolo), J-L. Canon(Grand Charleroi Hospital), J.F. Baurain, Paul M. Clément(Universitair Ziekenhuis Leuven), Alain Bols(AZ Sint-Jan), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell)
VUBIR (Vrije Universiteit Brussel)
May 1, 2015
Cited by 0
Related Papers
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2010|1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
|European Journal of Vascular and Endovascular Surgery|2020|709
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573